ScienceDaily
•79% Informative
An innovative phase 2 clinical trial led by Dana-Farber Cancer Institute in collaboration with 10 major brain tumor centers around the country has reported initial results in the Journal of Clinical Oncology .
The trial, called INSIGhT, is still underway testing additional therapies.
None of the therapies tested so far improved overall survival of patients.
The study's other co-first authors were Eudocia Quant Lee from Dana-Farber and Isabel Arrillaga-Romany from Massachusetts General Hospital .
Rahman : "This trial is more streamlined, but it's also rigorous, which makes it more likely that it will produce more reliable answers".
VR Score
90
Informative language
97
Neutral language
37
Article tone
formal
Language
English
Language complexity
65
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
long-living
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links